SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $20,944.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 4,400 shares of the company’s stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $4.76, for a total value of $20,944.00. Following the completion of the transaction, the insider directly owned 268,596 shares in the company, valued at approximately $1,278,516.96. The trade was a 1.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total value of $17,433.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,552.00.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Stock Up 2.3%

NASDAQ:SOPH traded up $0.11 during mid-day trading on Tuesday, reaching $4.96. The stock had a trading volume of 148,768 shares, compared to its average volume of 183,135. The company has a market capitalization of $339.71 million, a price-to-earnings ratio of -9.73 and a beta of 1.04. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70. The stock’s 50 day simple moving average is $4.74 and its two-hundred day simple moving average is $4.71. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. Equities analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently made changes to their positions in SOPH. Savvy Advisors Inc. acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at approximately $48,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at approximately $49,000. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the fourth quarter worth $49,000. Quadrature Capital Ltd acquired a new stake in SOPHiA GENETICS in the fourth quarter worth $54,000. Finally, XTX Topco Ltd acquired a new stake in SOPHiA GENETICS in the fourth quarter worth $55,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $7.00 price target on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Guggenheim upped their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Hold” and a consensus price target of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.